Skip to main content

Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery

Abstract

Purpose

We report the clinical findings and retinal function of a patient who presented retinal toxicity signs after cefuroxime use for a phacoemulsification surgery.

Methods

A 64-year-old man underwent a technically uneventful left eye cataract surgery. A standard intracameral dose of cefuroxime (0.1 mL of 10.0 mg/mL solution) was administered at the end of the surgery.

Results

At review 2 days later, he complained about left eye visual loss. Fundus examination revealed a diffuse retinal pallor with small intraretinal cysts. Optical coherence tomography scans showed a large retinal serous detachment with a schisis-like appearance of the outer nuclear layer. A slight global retinal dysfunction was recorded on ISCEV full-field electroretinogram. Fast clinical recovery was observed. Optical coherence tomography scans were back to normal within less than a week. Two months later, full-field electroretinogram showed no longer abnormalities.

Conclusion

It is the first report to our knowledge of a case of retinal toxicity with a standard dose. Kinetics and studies about cefuroxime toxicity are reviewed and discussed.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    Montan PG, Weide G, Setterquist H, Rylander M, Zetterström C (2002) Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 28(6):982–987

    PubMed  Article  Google Scholar 

  2. 2.

    Barry P, Seal DV, Gettinby G, Lees F, Peterson M, Revie CW, for the ESCRS Endophthalmitis Study Group (2006) ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery; preliminary results from a European multicenter study. J Cataract Refract Surg 32:407–410

    PubMed  Article  Google Scholar 

  3. 3.

    Lam PT, Young AL, Cheng LL, Tam PM, Lee VY (2010) Randomized controlled trial on the safety of intracameral cephalosporins in cataract surgery. Clin Ophthalmol 8(4):1499–1504

    Google Scholar 

  4. 4.

    Gupta MS, McKee HD, Saldana M, Stewart OG (2005) Macular thickness after cataract surgery with intracameral cefuroxime. J Cataract Refract Surg 31(6):1163–1166

    PubMed  Article  Google Scholar 

  5. 5.

    Hann JV, Lee LR (2006) Macular thickness after cataract surgery with intracameral cefuroxime. J Cataract Refract Surg 32(4):545 (author reply 545)

    PubMed  Article  Google Scholar 

  6. 6.

    Olavi P (2012) Ocular toxicity in cataract surgery because of inaccurate preparation and erroneous use of 50 mg/ml intracameral cefuroxime. Acta Ophthalmol 90(2):e153

  7. 7.

    Delyfer MN, Rougier MB, Leoni S, Zhang Q, Dalbon F, Colin J, Korobelnik JF (2011) Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg 37(2):271–278

    PubMed  Article  Google Scholar 

  8. 8.

    Qureshi F, Clark D (2011) Macular infarction after inadvertent intracameral cefuroxime. J Cataract Refract Surg 37(6):1168–1169

    PubMed  Article  Google Scholar 

  9. 9.

    Sakarya Y, Sakarya R (2010) Cefuroxime dilution error. Eur J Ophthalmol 20(2):460–461

    PubMed  Google Scholar 

  10. 10.

    Yoeruek E, Spitzer MS, Saygili O, Tatar O, Biedermann T, Yoeruek E, Bartz-Schmidt KU, Szurman P (2008) Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. J Cataract Refract Surg 34(12):2139–2145

    PubMed  Article  Google Scholar 

  11. 11.

    Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118(1):69–77

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Lockington D, Flowers H, Young D, Yorston D (2010) Assessing the accuracy of intracameral antibiotic preparation for use in cataract surgery. J Cataract Refract Surg 36(2):286–289

    PubMed  Article  Google Scholar 

  13. 13.

    Hui M, Lam PT, Cheung SW, Pang CP, Chan CY, Lam DS (2011) In vitro compatibility study of cephalosporin with intraocular irrigating solutions and intracameral medications. Clin Exp Ophthalmol 39(2):164–170

    Article  Google Scholar 

  14. 14.

    Shaarawy A, Meredith TA, Kincaid M, Dick J, Aguilar E, Ritchie DJ, Reichley RM (1995) Intraocular injection of ceftazidime. Effects of inflammation and surgery. Retina 15(5):433–438

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Kwok AK, Hui M, Pang CP, Chan RC, Cheung SW, Yip CM, Lam DS, Cheng AF (2002) An in vitro study of ceftazidime and vancomycin concentrations in various fluid media: implications for use in treating endophthalmitis. Invest Ophthalmol Vis Sci 43(4):1182–1188

    PubMed  Google Scholar 

  16. 16.

    Aguilar HE, Meredith TA, El-Massry A, Shaarawy A, Kincaid M, Dick J, Ritchie DJ, Reichley RM, Neisman MK (1995) Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Retina 15(5):428–432

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Koul S, Philipson A, Philipson BT, Arvidson S (1993) Intraocular levels of cefuroxime in inflamed rabbit eyes. Eur J Ophthalmol 3(2):61–65

    CAS  PubMed  Google Scholar 

  18. 18.

    Shahar J, Zemel E, Perlman I, Loewenstein A (2012) Physiological and toxicological effects of cefuroxime on the albino rabbit retina. Invest Ophthalmol Vis Sci 53(2):906–914

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Jain N, Bhatti MT (2012) Fingolimod-associated macular edema : incidence, detection and management. Neurology 78(9):672–680

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X (2013) Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 120(7):1432–1439

    PubMed  Article  Google Scholar 

  21. 21.

    Millay RH, Klein ML, Illingworth DR (1988) Niacin maculopathy. Ophthalmology 95(7):930–936

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Gass JD (1973) Nicotinic acid maculopathy. Am J Ophthalmol 76(4):500–510

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Fraunfelder FW, Fraunfelder FT, Illingworth DR (1995) Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 79(1):54–56

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  24. 24.

    Spirn MJ, Warren FA, Guyer DR, Klancnik JM, Spaide RF (2003) Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol 135(6):913–914

    PubMed  Article  Google Scholar 

  25. 25.

    Dajani HM, Lauer AK (2006) Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 41(2):197–200

    PubMed  Article  Google Scholar 

  26. 26.

    Jampol LM (1988) Niacin maculopathy: Ophthalmology 95(12):1704–1705

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Céline Faure.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Faure, C., Perreira, D. & Audo, I. Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery. Doc Ophthalmol 130, 57–63 (2015). https://doi.org/10.1007/s10633-014-9465-7

Download citation

Keywords

  • Cefuroxime
  • OCT
  • ERG
  • Retinal toxicity